Q1 F26 October 29, 2025 SAFE HARBOR STATEMENT During these presentations, and in response to your questions, certain items may be discussed which are not based entirely on historical facts. Any such items should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements to reflect events or circumstance ...

Summary of MicroPort (0853) Conference Call Company Overview - **Company**: MicroPort (0853 HK) - **Industry**: Healthcare, specifically medical devices Key Points Financial Performance - **1H2025 Results**: - Sales decline of less than 4% (excluding forex effects) - Adjusted net loss limited to US$110 million [1][5] - **Challenges**: - Domestic competition intensifying - Policy-induced price adjustments - International trade conflicts affecting sales growth across all segments, except for the surgical robot business [1][5] Future Outlook - **2H2025 Expectations**: - Anticipated recovery in sales momentum, particularly in the endovascular business during 2Q2025 - Significant growth potential in the surgical robot business as procurement funding in China normalizes [1][5] - **Management Comments**: - Awaiting insights on each business segment, especially orthopedics and CRM, during the interim earnings call [1][5] Investment Thesis - **Profitability Outlook**: - Expected decrease in net loss and potential for profitability by 2026, as per performance covenants from recent financing [5] - **Cost Optimization**: - Targeted cost optimization and inter-segment sales leverage expected to reduce opex/sales ratio from 96% in 2023 to below 50% by 2026 [5] - **Sales Growth**: - Estimated sales growth of approximately 20% per annum [5] Valuation - **Price Target**: - Dec-25 price target set at HK$8.60 based on DCF valuation [6] - **WACC Assumptions**: - Risk-free rate: 3.8% - Market risk premium: 6.4% - Beta: 1.5 - WACC: 12.7% [8] Risks - **Downside Risks**: - Worse-than-expected earnings - Higher-than-expected financial obligations, including CRM share repurchase - Dilution risk from further equity financing - Geopolitical risks [9] Additional Insights - **Convertible Loans**: - Adjusted net loss must not exceed US$110 million in 1H25 and US$55 million in 2025 as per performance covenant [1][5] - **Market Position**: - MicroPort manufactures high-value medical devices used across various disease areas, indicating a broad market presence [5] This summary encapsulates the critical financial and operational insights from the conference call regarding MicroPort, highlighting both current challenges and future opportunities within the healthcare sector.